glp 1 suicidal ideation Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study Frontiers | Suicidality as a

GLP-1 weight loss in Charlotte & Matthews with semaglutide, tirzepatide, oral options, and physician-supervised personalized care.

Methods In this open-label, single-center, casecontrol pilot study, patients with IIH (pwIIH) and a body mass index (BMI) of30 kg/m2 were offered to receive a GLP-1-RA (semaglutide, liraglutide) in addition to the usual care weight management (UCWM)

Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.

Nevertheless, more comprehensive studies are needed regarding the long-term efficacy, safety profiles, and clinical positioning of these agents

Altimmune will start a Phase III MASH study for pemvidutide this year, but Lillys triple agonist retatrutide and dual GLP-1/GCG agonists at Merck and Boehringer Ingelheim loom as competition.